Bayer’s Asundexian Reduces Recurrent Stroke Risk by 26 Percent in Landmark Phase III Trial

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...

February 10, 2026 | Tuesday | News
Bristol Myers Squibb Partners with Evinova to Advance AI Driven Clinical Trial Optimization

Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency ...

February 10, 2026 | Tuesday | News
Median Technologies Secures FDA Clearance for AI Powered eyonis LCS Lung Cancer Screening Software

eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unne...

February 10, 2026 | Tuesday | News
Peijia Medical Advances Global Expansion with EU MDR CE Mark Filing for GeminiOne TEER System

Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...

February 10, 2026 | Tuesday | News
Eisai’s Leqembi Autoinjector Clears Key Regulatory Step in China for Early Alzheimer’s Treatment

BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced  that the Biologics License Application (BLA) for the treatme...

February 10, 2026 | Tuesday | News
Genentech Advances Regulatory Path for Fenebrutinib After Phase III Success in Progressive MS

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...

February 09, 2026 | Monday | News
Novartis Expands US Innovation Footprint with USD 23 Billion R&D Push, Including New San Diego Research Hub

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including C...

February 09, 2026 | Monday | News
Konovo Acquires Rare Patient Voice to Deepen Access to Hard-to-Reach Rare Disease Communities

Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...

February 09, 2026 | Monday | News
Aminex Launches Mid-Stage Trial of Polyamine-Targeting Therapy in Solid Tumors

Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system  Aminex Therapeutics, Inc., a...

February 06, 2026 | Friday | News
Forma Life Sciences Established Following Acquisition of BioDuro’s California Manufacturing Assets

BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm,  announced the successful acquisition of Bi...

February 06, 2026 | Friday | News
QIAGEN CEO Thierry Bernard Highlights Resilient Growth as 2025 Results Beat Outlook and Set Strong 2026 Trajectory

Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...

February 06, 2026 | Friday | Company results
From Symptoms to Systems: The Rise of Multiomics in Disease Research

  In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...

February 04, 2026 | Wednesday | Interaction
From Injections to Pills: How Mass Spectrometry Is Reshaping Biopharma

  Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...

February 04, 2026 | Wednesday | Interaction
mRNA’s Next Act: Why Analytical Science Matters More Than Ever

As mRNA technologies move rapidly beyond COVID-19 into vaccines and therapies for cancer, rare diseases, and personalized medicine, scientific complexity i...

February 04, 2026 | Wednesday | Interaction

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close